Black Patients with Cancer and COVID-19 More Likely to Have Treatment Disruptions Than White Patients

TOP - September 2022 Vol 15, No 5 - COVID-19 & Cancer

According to data from the American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry, black or African-American patients with cancer and COVID-19 were more likely than non-Hispanic white patients to experience delays or disruptions in cancer treatment during the pandemic. These findings were presented during a poster session at the 2022 ASCO Annual Meeting.

“We found that among non-Hispanic black and African-American patients, there was a 3-times greater likelihood of treatment delay or discontinuation compared with non-Hispanic whites. This could lead to poorer outcomes and mortality related to cancer among blacks,” said lead investigator Jessica Y. Islam, PhD, MPH, Assistant Professor of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL. Dr Islam explained that there could be multiple reasons for these disparities. “Patients may fear coming to the clinic during peaks of SARS-CoV-2 [COVID-19] infection. Patient–provider communication may have broken down during this period,” she noted.

Analysis of ASCO Survey on COVID-19 in Oncology Registry

Data were obtained from the ASCO Survey on COVID-19 in Oncology Registry (March 2020-July 2021) and included 804 patients with breast cancer who were diagnosed with COVID-19 during their treatment at 46 practices across the United States. Breast cancer treatment delay or discontinuation was defined as any treatment postponed more than 2 weeks from the originally scheduled date.

Most patients included in the survey were aged ≥50 years (75%) and lived in urban settings (83%). The racial makeup of the sample was 13.3% non-Hispanic blacks, 11.7% Hispanics, 4.9% American Indians, 4.6% Asians, and 65% non-Hispanic whites. Of these 736 patients, 39% experienced treatment delay or discontinuation. Across all treatment modalities, the most common reason cited by clinicians (approximately 90%) for treatment delay or discontinuation was COVID-19.

Multivariate analyses were adjusted for age, number of comorbidities, cancer stage, Eastern Cooperative Oncology Group (ECOG) performance score, pandemic periods based on case peaks, and severity of COVID-19, including death, hospitalization, intensive care unit stay, and mechanical ventilation.

Severe treatment delays were reported in 1% of the study population versus 13% of the non-Hispanic blacks, which was the highest rate among the various racial groups. When broken down by urban versus rural patients, non-Hispanic black patients with cancer continued to experience significant delays and discontinuations in their treatment in both residential settings.

Impact of Rural versus Urban Settings

In a second analysis, Dr Islam and colleagues examined the effect of rural and urban settings on treatment delay and discontinuation in all patients with cancer diagnosed with COVID-19 during the pandemic who were included in the ASCO Survey on COVID-19 in Oncology Registry. This analysis included 499 patients living in a rural setting and 2689 patients living in an urban setting. At the time of COVID-19 diagnosis, rural patients were scheduled to receive drug-based therapy (72%), radiation therapy (8%), surgery (4%), or transplant (1%).

Compared with urban patients with cancer and COVID-19, rural patients were significantly more likely to be non-Hispanic white (81% vs 63%, respectively), reside in the Midwest (40% vs 27%, respectively), and have an ECOG performance score of 5 or 6 (36% vs 28%, respectively; P <.001 for all). Most rural patients received cancer care in urban areas (65%), but were more likely than urban patients to receive care at a rural clinic (35% vs 1%, respectively; P <.001). Rural patients were less likely than urban patients to receive care via telemedicine (18% vs 26%, respectively; P <.001). Patients living in rural areas were also less likely than those living in urban areas to have severe COVID-19 infection (31% vs 37%, respectively; P = .009) and to have COVID-19–related complications (17% vs 24%, respectively; P <.001).

“In a multivariate analysis, rural patients with cancer were 28% less likely to experience a treatment delay or discontinuation compared with urban patients with cancer during the pandemic,” Dr Islam said. “A potential explanation [for this finding] is that rural patients with cancer are more likely to have access to care, while urban patients with cancer are more likely to rely on urban transportation.”

Related Items
Multicancer Early Detection Blood Test May Change Cancer Screening Paradigms
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Determination Trial Confirms Importance of Individualizing Therapy for Newly Diagnosed Multiple Myeloma
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Multiple Myeloma
Researchers Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Promising New Approach to Treating Patients with Desmoid Tumors
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Radiation Therapy May Be Omitted for Some Older Women with Luminal A Breast Cancer
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Niraparib plus Abiraterone Combination Extends PFS in Men with CRPC and HRR Gene Mutations
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Prostate Cancer
Sotorasib Achieves Durable Responses in Patients with Metastatic NSCLC and KRAS Mutation
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Lung Cancer
Neoadjuvant Chemoimmunotherapy Shows Promise in Advanced Ovarian Cancer
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Ovarian Cancer
Dostarlimab Elicits 100% Complete Response Rate in Cohort of Patients with dMMR Rectal Cancer
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in ASCO 2022 Highlights
Peptide-Based CoVac-1 Vaccine Shows Promise Against COVID-19 in Patients with Cancer
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in COVID-19 & Cancer
Last modified: September 16, 2022